TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28826740
Drug: Routine hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine hormonal therapy only
Study: 21419287
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration of 4% articaine with 1:100,000 epinephrine
Study: 21419287
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration of 1 mL/30 mg of ketorolac tromethamine (after 0.9 mL of 4% articaine)
Study: 21419287
Drug: Supplemental buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental buccal infiltration of 1 mL/4 mg of dexamethasone
Study: 19548436
Drug: Qihong Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qihong Decoction (QHD) combined with routine treatment
Study: 16787719
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg/day) for 6 months
Study: 14747233
Drug: rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 4 mg b.i.d. for 12 weeks
Study: 14747233
Drug: rosiglitazone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone with co-infusion of exogenous insulin
Study: 14747233
Drug: nateglinide 60
Normalized name: nateglinide 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nateglinide 60 mg b.i.d. for 12 weeks
Study: 1908192
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of epidural diamorphine at a rate of 1 mg/hour (group 1)
Study: 1908192
Drug: Bolus doses
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus doses of epidural diamorphine 5 mg on demand (group 2)
Study: 20046181
Drug: Immunochromatographic test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunochromatographic test (ICT) for antibody
Study: 19040391
Drug: Ayurvedic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic formulation 'varuna and banana stem' (active treatment)
Study: 30043092
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 70 micro g/day (2800 IU/day)
Study: 22215183
Drug: 50,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU vitamin D3 monthly
Study: 22215183
Drug: Single 50,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 50,000 IU dose pre-departure
Study: 17394627
Drug: Biatain-Ibu non
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biatain-Ibu non adhesive foam dressing with ibuprofen
Study: 17394627
Drug: Biatain non
Normalized name: DRESSING,BIATAIN NON-ADHES FOAM 2X2.75IN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biatain non adhesive foam without ibuprofen
Study: 10671963
Drug: Nels cream
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nels cream (containing chloroxylenol and zinc oxide)
Study: 10671963
Drug: Vehicle of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of the Nels cream
Study: 1552408
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of nebulized cromolyn sodium
Study: 4053214
Drug: Lenampicillin (LAPC)
Normalized name: methampicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenampicillin (LAPC) - single dose (250 mg)
Study: 4053214
Drug: Amoxicillin (AMPC)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (AMPC) - single dose (500 mg)
Study: 4053214
Drug: Lenampicillin (LAPC)
Normalized name: methampicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenampicillin (LAPC) - multiple dose (250 mg twice a day for 8 days)
Study: 4053214
Drug: Amoxicillin (AMPC)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (AMPC) - multiple dose (500 mg twice a day for 8 days)
Study: 4053214
Drug: Amoxicillin (AMPC)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (AMPC)
Study: 29466159
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg daily for 5 days, then continued or switched to aspirin)
Study: 25524327
Drug: 60 µg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 µg/day selenium
Study: 20068435
Drug: Sonography-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonography-guided injection of botulinum toxin A into calf muscles
Study: 20068435
Drug: Electric stimulation-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electric stimulation-guided injection of botulinum toxin A into calf muscles
Study: 16232016
Drug: Fat emulsion
Normalized name: FAT EMULSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat emulsion administered through the ECMO circuit (1-3 g/kg/day)
Study: 16232016
Drug: Fat emulsion
Normalized name: FAT EMULSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat emulsion administered through separate intravenous access (1-3 g/kg/day)
Study: 9810316
Drug: Short-course preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course preoperative radiation therapy
Study: 9810316
Drug: Adjuvant radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiotherapy with conventional doses and concurrent fluorouracil-based chemotherapy
Study: 9810316
Drug: Postoperative combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative combination therapy
Study: 11362207
Drug: ABT-538 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-538 (300 mg, 400 mg, 500 mg, or 600 mg, administered twice daily)
Study: 979871
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (bicycle ergometer training for 15 minutes, 3 times weekly at 140 bpm)
Study: 30986535
Drug: Oral naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naltrexone (O-NTX)
Study: 26940112
Drug: Recovery-focused Cognitive
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery-focused Cognitive Behavioural Therapy for Older Adults (RfCBT-OA) plus treatment as usual (TAU)
Study: 24698798
Drug: Withholding dopaminergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withholding dopaminergic medication (OFF meds) during split-belt treadmill (SBT) walking
Study: 22369555
Drug: Full-mouth scaling
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth scaling and root planing (treatment group, n = 22)
Study: 22369555
Drug: No periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No periodontal treatment (control group, n = 18)
Study: 15827447
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg or 10 mg) once daily for up to 5 years
Study: 15827447
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg) once daily for up to 5 years
Study: 8913472
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% erythromycin
Study: 30900426
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SCIT) with Fagales pollen extracts
Study: 23173418
Drug: HIFU treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIFU treatment at 3.5 W in group A
Study: 23173418
Drug: HIFU treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIFU treatment at 4.0 W in group B
Study: 23173418
Drug: HIFU treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIFU treatment at 4.5 W in group C
Study: 23173418
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group D (no treatment)
Study: 15786480
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser (PDL) combined with photodynamic therapy (PDT) using systemic 5-aminolaevulinic acid (5-ALA) as the photosensitiser
Study: 30721231
Drug: EuroFIT intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EuroFIT intervention (12-week, group-based programme delivered in 12 weekly 90-minute sessions)
Study: 27751217
Drug: High-dose gamma
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose gamma globulin pulse therapy
Study: 19404806
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ropivacaine, 30 mg ketorolac, and 0.5 mg epinephrine (total volume 106 mL) infiltrated intraoperatively
Study: 19404806
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ropivacaine, 30 mg ketorolac, and 0.1 mg epinephrine injected intraarticularly via a catheter 21 hours postoperatively
Study: 17984806
Drug: 30 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mug Vi polysaccharide vaccine (revaccination)
Study: 17984806
Drug: Vi polysaccharide
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi polysaccharide vaccine (primary vaccination)
Study: 9884851
Drug: Morphine 0.2
Normalized name: morphine 0.23 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.2 mg mL‐1 plus lignocaine 3.2 mg mL‐1 (group ML)
Study: 9884851
Drug: Morphine 0.2
Normalized name: morphine 0.23 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.2 mg mL‐1 (group M)
Study: 25828348
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg losartan daily
Study: 25828348
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg losartan daily
Study: 25828348
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose losartan
Study: 23955995
Drug: Metformin (lean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (lean subgroup, BMI < 25 kg/m(2))
Study: 19410976
Drug: (1,3)(1,6)-beta-D-glycan (BDG)
Normalized name: beta-D-ribose
Approvals — FDA: no, EMA: no, PMDA: no
Description: (1,3)(1,6)-beta-D-glycan (BDG) 3 x 0.5 g daily for 4 weeks
Study: 19410976
Drug: Placebo (waxy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (waxy maize starch) 3 x 0.5 g daily for 4 weeks
Study: 8197931
Drug: Radical prostatectomy
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical prostatectomy after hormonal treatment (560 mg of estramustine phosphate daily for 6 weeks)
Study: 29093779
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HA and DBM
Study: 23784924
Drug: Methylprednisolone 16
Normalized name: methylprednisolone 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 16 mg/kg/day (≤1000 mg) for 3 days
Study: 12953307
Drug: CDDP/epi gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDDP/epi gel
Study: 10081698
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal treatment (NHT) for three months
Study: 1838772
Drug: Couple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couple therapy (n = 33), consisting of five monthly sessions attended by two family therapists.
Study: 1838772
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without couple therapy (n = 30).
Study: 24622016
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 0.5 mg/1 ml
Study: 24622016
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 2 mg/1 ml
Study: 24622016
Drug: Sodium Chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Chloride (NS) 0.9% solution (1 ml)
Study: 20528293
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality exposure (VRE) therapy
Study: 20528293
Drug: Present‐centered therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present‐centered therapy (PCT)
Study: 18808630
Drug: Music group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music group (listened to selected sedative music using headphones)
Study: 10230185
Drug: Antipsychotic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic agents
Study: 1646182
Drug: Fluoxetine (FXT)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FXT) 60 mg daily (n = 11)
Study: 8555377
Drug: Fluoxetine (FXT)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FXT)
Study: 6941408
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg domperidone i.v.
Study: 28249030
Drug: Fixed low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed low dose ESA (4000 IU epoetin alfa equivalent weekly)
Study: 28249030
Drug: Fixed high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed high dose ESA (18,000 IU epoetin alfa equivalent weekly)
Study: 25161160
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus voglibose
Study: 22935052
Drug: Placebo 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 mg orally three times daily for 14 days followed by Domperidone 10 mg orally three times daily for 14 days
Study: 19834698
Drug: Dopaminergic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic drugs (e.g., levodopa)
Study: 19834698
Drug: Nondopaminergic drugs
Normalized name: MAO B Inhibitors, dopaminergic anti-parkinson drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondopaminergic drugs (e.g., folic acid, methylphenidate, aplindore, levetiracetam, Neu 120)
Study: 19834698
Drug: Newly developed
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly developed drugs with known mode of action
Study: 15764958
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of Abacavir (ABC) administered once daily
Study: 15764958
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of Abacavir (ABC) administered twice daily
Study: 10641957
Drug: Sustained-release diltiazem
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release diltiazem (INTERCEPT trial)
Study: 26178160
Drug: Melatonin 20
Normalized name: melatonin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 20 mg orally each night for 1 week
Study: 20679619
Drug: EOC +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EOC + P (epirubicin 50 mg/m(2), oxaliplatin 130 mg/m(2), capecitabine 1,000 mg/m(2)/d + P 9 mg/kg every 3 weeks)
Study: 20679619
Drug: EOC (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOC (standard dose)
Study: 18215666
Drug: Primary intraosseous
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary intraosseous injection of 1.4 mL of 2% lidocaine with epinephrine
Study: 18215666
Drug: Repeated intraosseous
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated intraosseous injection given 30 minutes after the primary injection
Study: 18215666
Drug: Mock injection
Normalized name: mockernut extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mock injection at 30 minutes
Study: 16618470
Drug: Active Physical
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Physical Treatment (APT, n = 52)
Study: 16618470
Drug: Cognitive-Behavioral Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Treatment (CBT, n = 55)
Study: 16618470
Drug: Combined Treatment
Normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Treatment (CT, n = 55)
Study: 14725386
Drug: New toothbrush
Approvals — FDA: no, EMA: no, PMDA: no
Description: New toothbrush plus plaque disclosing tablet (SIGNAL Integral)
Study: 14725386
Drug: Marketed toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Marketed toothbrush (Oral B Cross Action)
Study: 8219659
Drug: Cilazapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (2.5 mg/day) after placebo treatment
Study: 3305057
Drug: N-acetylcysteine (NAC),
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC), peroral dose 200 mg three times daily
Study: 29249276
Drug: Adjunctive rifampicin
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive rifampicin (600 mg or 900 mg per day for 2 weeks)
Study: 22820788
Drug: Hydroxychloroquine, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine, 400 mg once daily for 48 weeks
Study: 18275682
Drug: Supraphysiological doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraphysiological doses of PYY3-36
Study: 10529526
Drug: AmF 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmF 1% F(‐) solution applied twice a year on the enamel surfaces of the first permanent molars for 5 years
Study: 10529526
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution applied twice a year on the enamel surfaces of the first molars for 5 years
Study: 10529526
Drug: AmF 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmF 1% F(‐) solution in low-SMS subjects
Study: 10529526
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution in low-SMS subjects
Study: 10529526
Drug: AmF 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmF 1% F(‐) solution in high-SMS subjects
Study: 10529526
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution in high-SMS subjects
Study: 1522289
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine gel (daily application for one week)
Study: 25881564
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood injections (ABIs)
Study: 19161758
Drug: Levosimendan (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (12 microg/kg bolus, followed by an infusion of 0.2 microg/kg/min)
Study: 9474184
Drug: 3-month course
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month course of 300 mg neoadjuvant cyproterone acetate daily
Study: 2371437
Drug: Amoxycillin 1
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 1 g twice daily with probenecid
Study: 2371437
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose amoxycillin 3 g twice daily
Study: 782773
Drug: 10 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/70 kg dextroamphetamine sulfate and 50 mug/kg THC from marihuana cigarette
Study: 782773
Drug: 10 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/70 kg dextroamphetamine sulfate and 25 mug/kg THC from marihuana cigarette
Study: 782773
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dextroamphetamine and marihuana
Study: 23216615
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg apixaban, twice daily
Study: 23216615
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg apixaban, twice daily
Study: 21216852
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion during normoglycemia
Study: 14514589
Drug: Inhaled regular
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled regular insulin (80, 160, or 240 units) via Aerodose insulin inhaler
Study: 14514589
Drug: Subcutaneously injected
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously injected regular insulin (8, 16, or 24 units)
Study: 14514589
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of total insulin absorption (insulin AUC) versus total metabolic effect (GIR-AUC)
Study: 10718776
Drug: Risedronate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (30 mg single oral dose)
Study: 1417176
Drug: Surgery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery and chemotherapy (n = 77)
Study: 22199063
Drug: 0.1% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tacrolimus ointment, twice daily for 6 months
Study: 22199063
Drug: 0.05% fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% fluticasone propionate cream, once daily for 6 months
Study: 21589776
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (head, neck, face, shoulder, hand, leg, and back massage every night for one month)
Study: 21589776
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intervention except standard treatment)
Study: 18416219
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular starch in combination with Ringer Lactate solution (LMSRL)